RNA-based therapeutics and diagnostics represent biotechnology's future, yet a single trace of RNase contamination destroys RNA molecules rendering products ineffective and diagnostic results meaningless. RNase activity testing ensures absence of ribonucleases that could compromise RNA-based therapeutics, diagnostic devices, or research tools where enzymatic degradation persists even after proteins are denatured. Using fluorometric detection of RNA substrate degradation, this analysis provides sensitive measurement of enzymatic activity that survives denaturation, sterilization, and storage conditions that eliminate viable organisms. For manufacturers of devices used in molecular diagnostics, gene therapy, or mRNA applications including COVID-19 vaccines, confirming RNase-free status protects product integrity and ensures reliable performance in RNA-sensitive applications. The fluorometric method detects RNase activity levels that could degrade RNA samples or therapeutics during collection, transport, or storage, even when protein levels appear acceptable by standard testing methods. This becomes critical for devices like sample collection tubes where trace RNase causes false-negative diagnostic results, pipette tips used in RNA research where contamination ruins experiments, and microfluidic chips for RNA analysis where nuclease activity destroys analytes before detection. Manufacturing processes including metal passivation, plastic molding, and assembly can introduce RNase contamination from equipment, operators, or raw materials, requiring validation that processing achieves RNase-free status. The testing proves particularly valuable when troubleshooting product performance issues in RNA applications, validating new suppliers or manufacturing processes, or supporting RNase-free marketing claims that differentiate products in molecular biology markets.